Adial Pharmaceuticals reported $5.9 million in cash and cash equivalents as of December 31, 2025, up from $3.8 million a year earlier, and anticipates funding operations into the second half of 2026. Research and development expenses decreased by 19% to save $609 thousand, while general and administrative costs rose 2%.

The company achieved positive results from the AD04-103 pharmacokinetic study, received FDA feedback supporting its in vitro bridging strategy and completed an End-of-Phase 2 meeting that aligns Phase 3 development plans. Recent policy discussions indicate potential approval based on a single robust pivotal trial plus confirmatory evidence, which could reduce late-stage clinical costs by tens of millions of dollars.

Adial engaged Cytel Inc. for advanced trial design and partnered with Genomind on precision medicine testing. It secured U.S. manufacturing agreements with Cambrex and Thermo Fisher Scientific and signed a framework with Molteni Farmaceutici outlining up to $60 million in potential Europe commercialization milestones and royalties.

The company strengthened its U.S. patent portfolio with grants covering genotype-specific opioid disorder treatments and genetic-based approaches to Alcohol Use Disorder. A Patent Cooperation Treaty application was filed to extend core asset protection internationally through at least 2045.